Credit: Shutterstock photoCalyxt, a developer of gene-edited crop traits spun out of Cellectis, raised $56 million by offering 7 million shares at $8, the low end of the slashed $8 to $10 range. It previously filed to offer 6.1 million shares at a range of $15 to $18 per share. Calyxt plans to list on the Nasdaq under the symbol CLXT. Citi, Jefferies and Wells Fargo Securities acted as lead managers on the deal.
The article Calyxt prices IPO at $8, the low end of the slashed range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
